FTC Says Ivax Misconstrues Hatch-Waxman Rules

Law360, New York (April 8, 2005, 12:00 AM EDT) -- The U.S. Food and Drug Administration should reject Ivax Pharmaceutical Inc.’s "flawed" petition for a 180-day marketing exclusivity period for its generic version of Merck & Co.’s cholesterol-lowering drug Zocor, the Federal Trade Commission argued in a brief filed with the court this week.

Ivax submitted an abbreviated new drug application (ANDA) for generic Zocor in 2000 and was entitled to exclusivity under two of Merck & Co.'s patent claims as mandated by the Hatch-Waxman Act.

Under the Hatch-Waxman Act, Congress afforded the first filer of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.